A Phase 2 Study of BGB-11417 in People With Waldenström's Macroglobulinemia

Full Title

An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination with Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia

Purpose

In this study, researchers want to learn if BGB-11417 works well against Waldenström’s macroglobulinemia (WM). The people in this study have WM that keeps growing or came back after treatment.

BGB-11417 blocks a protein called Bcl-2, which helps blood cancer cells to live and grow. It is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have WM that keeps growing or came back even after treatment.
• Have recovered from the serious side effects of prior cancer therapies before taking BGB-11417.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 18 or older.

Contact

For more information and to see if you can join this study, please call Dr. Lia Palomba’s office at 646-608-3711.